In December 2025, I wrote about peptides and why they matter across skincare, nutrition, and injectable applications. That article laid out the biology. This one covers the regulatory landscape, which has shifted significantly in the last four months.
If you are a patient using injectable peptides, considering them, or have been told they are no longer available, here is what’s happening.
The Regulatory Timeline
In late 2023, the FDA moved 19 peptides from Category 1 to Category 2 on its bulk drug substances list. Category 2 means the FDA identified unresolved safety concerns and the peptides became ineligible for routine compounding by traditional 503A pharmacies. For patients, this meant that compounds like BPC-157, TB-500, and MOTS-c effectively disappeared from legitimate clinical channels. Compounding pharmacies that had been producing them for physician-supervised use were forced to stop.
On April 15, 2026, HHS Secretary Kennedy confirmed the removal of 12 peptides from Category 2. The companies that had originally nominated these substances for safety review withdrew their nominations, and the peptides were removed from the restricted list, effective April 23, 2026.
The 12 peptides removed include BPC-157, TB-500, MOTS-c, GHK-Cu (injectable), KPV, Semax, Epitalon, Emideltide (DSIP), Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, and Melanotan II.
What This Does and Does Not Mean
This is where precision matters. Removal from Category 2 does not make these peptides legal to compound. It removes one specific barrier, but these substances remain outside the scope of the FDA’s interim enforcement policy. They are not FDA-approved drugs. A compounding pharmacy cannot start producing BPC-157 tomorrow on the basis of this change alone.
What it does is open a formal pathway for evaluation. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) will convene on July 23 and 24, 2026, at the FDA’s White Oak Campus in Silver Spring, Maryland, to review seven of the twelve peptides for potential inclusion on the 503A bulks list. Day one covers BPC-157, KPV, TB-500, and MOTS-c. Day two covers Emideltide (DSIP), Semax, and Epitalon. The remaining five peptides, including GHK-Cu (injectable), PEG-MGF, and Melanotan II, are scheduled for a separate PCAC meeting before the end of February 2027.
If the PCAC recommends inclusion and the FDA concurs, a formal rulemaking process would follow. That process has its own timeline. Realistically, even in an optimistic scenario, we are looking at late 2026 at the earliest before any of these peptides could be compounded through legitimate pharmacy channels with full regulatory clarity.
The GLP-1 Situation
A related but distinct issue involves peptide-based medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). When these drugs faced national shortages beginning in 2022, compounding pharmacies began producing lower-cost alternatives. The FDA has since determined that the tirzepatide shortage has been resolved, which removes the legal basis for compounding versions of that specific drug. Eli Lilly and Novo Nordisk have pursued aggressive legal action against compounders who continue to produce alternatives.
This is a separate regulatory fight from the BPC-157 and TB-500 discussion, but it shapes the broader environment. The tension between pharmaceutical manufacturers, compounding pharmacies, and the FDA is real and ongoing, and it affects how quickly the peptide compounds many patients are interested in will become consistently available.
What This Means for Patients
Three things matter if you are a patient considering peptide therapy:
First, the direction of travel is toward expanded access, not restriction. The removal of 12 peptides from Category 2 and the scheduling of formal PCAC review meetings represent meaningful forward movement. This is not the FDA reversing its position on safety. It is the FDA creating a structured process to evaluate these compounds rather than leaving them in regulatory limbo.
Second, the distinction between a peptide being reviewed and a peptide being approved is critical. Until the PCAC process concludes and formal rulemaking follows, these compounds exist in an intermediate state. Patients should be cautious about any provider or supplier claiming they can legally provide these peptides based on the April 2026 change alone. Source matters. Oversight matters.
Third, the underlying biology has not changed. The reasons peptides like BPC-157 and TB-500 generated clinical interest, their roles in tissue repair, inflammation modulation, angiogenesis, and recovery, remain sound. Published research continues to support their mechanisms. What has changed is the regulatory framework catching up to clinical reality, which is a net positive for patients who want access to these therapies under proper medical supervision.
Our Position
We have always maintained that injectable peptides belong under physician oversight, sourced from verified compounding pharmacies, and administered within a clinical framework. That position has not changed. As the regulatory landscape evolves over the remainder of 2026 and into 2027, we will continue to offer peptide therapies that meet our standard for safety, sourcing, and clinical evidence.
If you have questions about peptides, including what is currently available and what we expect to become available as the PCAC process unfolds, we are here to discuss them during a consultation.
Dr. Chuma Chike-Obi is a board-certified plastic surgeon and founder of 360 Plastic Surgery in Austin, Texas. Named Best Plastic Surgeon by Austin Fit Magazine and a Super Doctors® 2025 honoree, Dr. Chike-Obi and his team specialize in natural-looking results through both surgical and non-surgical approaches.
Written and reviewed by Dr. Chuma Chike-Obi, MD
